Non-small cell lung cancer
Conditions
Interventions
None listed
Sponsors
National Cancer Center Hospital East
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. 20 years old or above 2. Pathologically confirmed non-small cell lung cancer (regardless of histology or cytology) 3. Clinical stage III, stage IV or postsurgical relapse at the time of registration. 4. The disease is inoperable and ineligible for radical radiation therapy, and chemotherapy is planned. 5. The subject is chemotherapy naive or had a history of chemotherapy of no more than 2 regimens. 6. Enrollment in a prospective observational study to clarify the clinicopathological and molecular biological features of lung cancer with low-frequency genetic changes, such as the RET fusion gene, in non-small cell lung cancer. 7. The patient who can provide blood sample within 4 weeks of tumor sample collection. The patient is going to be excluded if prescribed blood sample cannot be collected. 8. With written informed consent.
Exclusion criteria
Exclusion criteria: None
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Concordance of Guardant360 data for ctDNA and NGS data for tumor samples by Oncomine Comprehensive Assay (OCA) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.The percentage of patients observed to have alterations to the 7 driver genes (EGFR, ALK, ROS1, BRAF, MET, RET, ERBB2). 2.Clinical efficacy (response rate, time to treatment failure, overall survival period) of molecular-targeted therapy in patients in whom genetic alterations are detected by Guardant360. 3.Time course of molecular profiling change which are related with drug resistance. | — |
Countries
Japan
Contacts
Public ContactYuko Usui, Shigeki Umemura, Koichi Goto
National Cancer Center Hospital East Department of Thoracic Oncology
Outcome results
None listed